You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Qiagen said that its FlexiPlate siRNA reagent libraries are now available in Labcyte Echo-qualifed microplates.
The new microplate format allows the siRNAs to be used with the Echo liquid handler.
By Doug Macron
Leonardo Biosystems said this week that it has received the second half of a $2.5 million grant from the Texas Emerging Technology Fund to help develop its multi-stage drug-delivery technology.
The first half of the grant was received in April 2010.
Arrowhead Research this week released a white paper detailing the dynamic polyconjugate siRNA-delivery technology it picked up through its recent acquisition of Roche's RNA therapeutics assets.
Access Pharmaceuticals this week announced that it has signed a deal under which its CobaCyte and CobOral siRNA delivery technologies will be evaluated by an undisclosed pharmaceutical company.
Marina Biotech this week announced that the incorporation of a proprietary technology into an siRNA could reduce toxicity caused by microRNA-like off-target activity.
Silence Therapeutics this week announced that it has signed a deal under which one of its proprietary siRNA delivery technologies will be evaluated by an undisclosed “global pharmaceutical” company.
The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.
New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.
In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.
Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.